Claims
- 1. A tricyclic compound represented by the following formula (I): ##STR89## wherein R.sup.1 represents hydrogen, halogen or lower alkyl; A represents cyano, carboxyl, tetrazolyl, cyano-substituted phenyl, carboxyl-substituted phenyl or tetrazolyl-substituted phenyl; V represents --(CH.sub.2).sub.m -- wherein m is an integer of 0 to 2; W represents ##STR90## wherein R.sup.2, R.sup.3 and R.sup.4 independently represent hydrogen, halogen, lower alkyl, cycloalkyl, halogenated lower alkyl, hydroxy, lower alkoxy, amino, lower alkylamino, carboxyl or lower alkoxycarbonyl; and Q.sup.1 --Q.sup.2 --Q.sup.3 --Q.sup.4 represents N.dbd.CH--CH.dbd.CH, CH.dbd.CH--CH.dbd.CH or CH.sub.2 --CH.sub.2 --CH.sub.2 --CH.sub.2, ##STR91## wherein R.sup.2, R.sup.3 and R.sup.4 have the same meanings as defined above, ##STR92## wherein R.sup.5 and R.sup.6 independently represent hydrogen, lower alkyl or cycloalkyl; and R.sup.7 represents carboxyl, lower alkoxycarbonyl, carbamoyl or hydroxymethyl or ##STR93## wherein R.sup.8 and R.sup.9 independently represent hydrogen or lower alkyl; and Q represents N or CH; X.sup.1 --X.sup.2 --X.sup.3 represents CH.dbd.CH--CH.dbd.CH, S--CH.dbd.CH or CH.dbd.CH--S; Y represents CH.sub.2 CH.sub.2 and Z.sup.1 --Z.sup.2 represents N--(CH.sub.2).sub.n -- wherein n is an integer of 1 to 3 or a pharmaceutically acceptable salt thereof.
- 2. The tricyclic compound as claimed in claim 1, wherein
- R.sup.1 is H;
- X.sup.1 --X.sup.2 --X.sup.3 is CH.dbd.CH--CH.dbd.CH;
- m in V is 0;
- and V is oriented at the para-position from the Z.sup.1 atom in the tricyclic system.
- 3. The tricyclic compound as claimed in claim 2, wherein A is tetrazolyl.
- 4. The tricyclic compound as claimed in claim 3, wherein Z.sup.1 --Z.sup.2 is N--CH.sub.2.
- 5. The tricyclic compound as claimed in claim 4, wherein W is 2-alkyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl.
- 6. The tricyclic compound as claimed in claim 5, wherein alkyl is ethyl or cyclopropyl.
- 7. The tricyclic compound as claimed in claim 4, wherein W is 7-carboxy-2-ethyl-benzimidazol-1-yl.
- 8. The tricyclic compound as claimed in claim 4, wherein W is N-(1-carboxy-2-methyl)propyl-N-valeryamino.
- 9. The tricyclic compound as claimed in claim 2, wherein
- A is carboxyl;
- Z.sup.1 --Z.sup.2 is N--CH.sub.2 ;
- and W is 5,7-dimethyl-2-ethyl-3H-imidazo[4,5-b]pyridin-3-yl.
- 10. A pharmaceutical composition comprising a pharmaceutical carrier and as an active ingredient, an effective amount of the compound as defined by claim 1.
Priority Claims (1)
Number |
Date |
Country |
Kind |
3-347294 |
Dec 1991 |
JPX |
|
Parent Case Info
This application is a continuation-in-part of prior U.S. patent application Ser. No. 07/996,694, filed Dec. 24, 1992, now abandoned.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4122186 |
Lafon |
Oct 1978 |
|
5128356 |
Naka et al. |
Jul 1992 |
|
Foreign Referenced Citations (2)
Number |
Date |
Country |
0400974 |
Dec 1990 |
EPX |
0443983 |
Aug 1991 |
EPX |
Non-Patent Literature Citations (1)
Entry |
Journal Medical Chemistry, vol. 34 (1991) 2919-22. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
996694 |
Dec 1992 |
|